Do you need a starting point for a Serialization User Requirement Spec (URS)?

October 10, 2012

One of the challenges to starting any User Requirement Specification (URS) is to envision a structure which can allow for traceability as the project continues.  The attached sample URS is a starting point which is laid out in tabular format to allow easy integration into a Requirements Traceability Matrix (RTM).  The URS is separated into logical sections to prompt the writer to consider what requirements are appropriate for their specific implementation an organized way.  Requirement examples provided in each section are intended to provide some initial ideas which can be further embellished and added to as appropriate for a project.

Once a structure has been established, the other major challenge is to write good requirements. The key attributes of good requirements are:
 
  • Each requirement should be concise.  No more than 200 words.
  • Each requirement should be measurable.  Requirements like “User Friendly” are hard to test.
  • Requirements should only be stated once.  Multiple requirements stating the same need are often contradictory.

This document does not necessarily include all the requirements for your system, but I hope you find this a better starting point than a blank screen!

Download the Microsoft Word version here:

Screenshot of 'Considering URS document'

TAGS:

March 5, 2012

Food and Cosmetic Ingredients that are also Excipients in Drug Products – OGD Policy

In a recent teleconference with senior officials in the Office of Generic Drugs (OGD) at the FDA, it was conveyed that it is the policy of OGD in determining the safety of excipients to rely...

The IND is More Just an FDA Submission: It’s a Regulatory Positioning Strategy

For decades, FDA's Investigational New Drug (IND) application has been viewed primarily as a regulatory gateway. Submit the application, obtain FDA's approval to proceed, and begin clinical trials....

Business professionals meeting gathered around table

Maximizing the Value of FDA Pre-IND Meetings for Successful 505(b)(2) NDA Submissions

For drug developers leveraging the 505(b)(2) pathway, the FDA Pre-Investigational New Drug (Pre-IND) meeting is a strategic opportunity that can shape the trajectory of an entire development program....